The estimated Net Worth of Vijay K Lathi is at least 89.5 百万$ dollars as of 22 February 2018. Vijay Lathi owns over 45,723 units of iRhythm Technologies Inc stock worth over 8,531,967$ and over the last 8 years Vijay sold IRTC stock worth over 81,012,878$.
Vijay has made over 9 trades of the iRhythm Technologies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Vijay sold 114,018 units of IRTC stock worth 7,575,356$ on 8 March 2018.
The largest trade Vijay's ever made was selling 645,000 units of iRhythm Technologies Inc stock on 12 May 2017 worth over 22,381,500$. On average, Vijay trades about 183,898 units every 50 days since 2016. As of 22 February 2018 Vijay still owns at least 114,018 units of iRhythm Technologies Inc stock.
You can see the complete history of Vijay Lathi stock trades at the bottom of the page.
Vijay's mailing address filed with the SEC is C/O NEW LEAF VENTURES, 7 TIMES SQUARE, SUITE 3502, NEW YORK, NY, 10036.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over 124,847,276$ worth of iRhythm Technologies Inc stock and bought 150,000 units worth 2,550,000$ . The most active insiders traders include Holdings A/S Novo、Vijay K Lathi、Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of 1,872,546$. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth 96,506$.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: